-

Vetoquinol: 2025 Calendar of Financial Communication

LURE, France--(BUSINESS WIRE)--Regulatory News:

Vetoquinol (Paris:VETO) published its calendar of financial communication for 2025.

January 30, 2025

2024 Annual Sales (after market)

March 20, 2025

2024 Annual results (confcall after market)

April 24, 2025

2025 First quarter sales (after market)

May 22, 2025

Annual shareholders’ meeting

June 6, 2025

Dividend payment

September 11, 2025

2025 First semester results (confcall after market)

October 28, 2025

2025 Third quarter sales (after market)

Next update: Annual Sales 2024, January 30th, 2025 after market close

ABOUT VETOQUINOL

Vetoquinol is a leading international player in animal health, with operations in Europe, the Americas and Asia/Pacific.

Independent and a pure player, Vetoquinol innovates, develops and markets veterinary medicines and non-medicated products for farm animals (cattle, pigs) and pets (dogs, cats).

Since its creation in 1933, Vetoquinol has combined innovation and geographic diversification. The strengthening of the product portfolio and acquisitions in high-potential territories ensure hybrid growth for the Group. At June 30, 2024, Vetoquinol employed 2,519 people.

Vetoquinol has been listed on Euronext Paris since 2006 (mnemonic code: VETO).

The Vetoquinol share is eligible for the French PEA and PEA-PME personal equity plans.

Contacts

FOR MORE INFORMATION, CONTACT:

VETOQUINOL

Investor Relations
Fanny Toillon
Tel.: +33 (0)3 84 62 59 88
relations.investisseurs@vetoquinol.com

Vetoquinol

BOURSE:VETO
Release Versions
EnglishFrench

Contacts

FOR MORE INFORMATION, CONTACT:

VETOQUINOL

Investor Relations
Fanny Toillon
Tel.: +33 (0)3 84 62 59 88
relations.investisseurs@vetoquinol.com

More News From Vetoquinol

Vetoquinol: Availability of the 2025 Universal Registration Document

LURE, France--(BUSINESS WIRE)--Regulatory News: On 29 April 2026, Vetoquinol (Paris:VETO) filed its 2025 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format). The 2025 Universal Registration Document in ESEF and PDF formats (reproduction of the official version of the Universal Registration Document in ESEF format) is available to the public under the conditions provided by applicable regulations and may be consulted on the “...

Vetoquinol: Sales for 1st Quarter 2026

LURE, France--(BUSINESS WIRE)--Regulatory News: Vetoquinol (Paris:VETO): Sales for the first quarter of 2026 amounted to €125 million, down 4.3% on a reported basis, flat (-0.3%) at constant exchange rates and up 1.2% compared to the previous year at constant exchange rates and excluding the complementary product line simplification program. The impact of exchange rates was historically high during the first quarter, reaching -€5.2 million, primarily in the United States (-€2.9 million) and Ind...

Vetoquinol: 2025 Annual Results

LURE, France--(BUSINESS WIRE)--Regulatory News: Commenting on the 2025 fiscal year, Matthieu Frechin, Chairman and CEO of Vetoquinol (Paris:VETO), stated, “In an extremely volatile environment, Vetoquinol has once again this year demonstrated the resilience of its business model, driven by a long-term strategic vision which, combined with our proactive management of expenses, enables us to deliver a healthy level of profitability. We will actively pursue this strategy, relying in particular on...
Back to Newsroom